AU2017290060B2 - Boronic acid derivatives and therapeutic uses thereof - Google Patents

Boronic acid derivatives and therapeutic uses thereof Download PDF

Info

Publication number
AU2017290060B2
AU2017290060B2 AU2017290060A AU2017290060A AU2017290060B2 AU 2017290060 B2 AU2017290060 B2 AU 2017290060B2 AU 2017290060 A AU2017290060 A AU 2017290060A AU 2017290060 A AU2017290060 A AU 2017290060A AU 2017290060 B2 AU2017290060 B2 AU 2017290060B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
alkyl
group
amido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017290060A
Other languages
English (en)
Other versions
AU2017290060A1 (en
Inventor
Tomasz Glinka
Scott Hecker
Raja K. Reddy
Olga Rodny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qpex Biopharma Inc
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of AU2017290060A1 publication Critical patent/AU2017290060A1/en
Application granted granted Critical
Publication of AU2017290060B2 publication Critical patent/AU2017290060B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017290060A 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof Active AU2017290060B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357165P 2016-06-30 2016-06-30
US62/357,165 2016-06-30
PCT/US2017/039787 WO2018005662A1 (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2017290060A1 AU2017290060A1 (en) 2018-12-20
AU2017290060B2 true AU2017290060B2 (en) 2021-07-22

Family

ID=60785544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017290060A Active AU2017290060B2 (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Country Status (23)

Country Link
US (5) US10294249B2 (https=)
EP (1) EP3478693B1 (https=)
JP (1) JP7060245B2 (https=)
KR (1) KR102403296B1 (https=)
CN (1) CN109415386B (https=)
AU (1) AU2017290060B2 (https=)
BR (1) BR112018077015B1 (https=)
CA (1) CA3026582A1 (https=)
CL (1) CL2018003681A1 (https=)
CO (1) CO2018013978A2 (https=)
DK (1) DK3478693T3 (https=)
ES (1) ES2894251T3 (https=)
IL (1) IL263450B (https=)
MX (1) MX389349B (https=)
MY (1) MY196909A (https=)
PH (1) PH12018502747A1 (https=)
PL (1) PL3478693T3 (https=)
PT (1) PT3478693T (https=)
SA (1) SA518400742B1 (https=)
SG (1) SG11201811549UA (https=)
UA (1) UA124464C2 (https=)
WO (1) WO2018005662A1 (https=)
ZA (1) ZA201808327B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX389349B (es) * 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
BR112021010095A2 (pt) * 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas
EP3986419B1 (en) * 2019-06-19 2025-05-14 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
US20230151029A1 (en) * 2020-03-18 2023-05-18 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
JP2023538645A (ja) * 2020-08-20 2023-09-08 フェーノ・セラピューティクス・カンパニー・リミテッド ボロン酸化合物
JP2024512793A (ja) * 2021-04-05 2024-03-19 キューペックス バイオファーマ， インコーポレイテッド セフチブテン投与レジメン
JP2024514055A (ja) * 2021-04-13 2024-03-28 上海拓界生物医薬科技有限公司 β－ラクタマーゼ阻害剤としてのホウ酸誘導体
CN113150022B (zh) * 2021-04-23 2022-12-06 四川大学 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途
IL312198A (en) * 2021-10-19 2024-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Derivation of tricyclic boronic acid, a method for its preparation and application
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
CN114716465B (zh) * 2022-05-06 2024-05-24 上海中医药大学 一种双环硼酸酯类化合物的制备方法及其应用
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
WO2025111328A1 (en) 2023-11-21 2025-05-30 VenatoRx Pharmaceuticals, Inc. Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用
WO2026067428A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 硼酸衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) * 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) * 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO1998056392A1 (en) 1997-06-13 1998-12-17 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
MXPA02003175A (es) 1999-09-25 2002-09-30 Smithkline Beecham Plc Derivados de piperazina como antagonsitas de 5-ht1b.
WO2001030149A1 (en) 1999-10-28 2001-05-03 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
US6916803B2 (en) 2000-09-14 2005-07-12 Pantherix, Ltd. 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
CN100528846C (zh) 2002-09-11 2009-08-19 株式会社吴羽 胺化合物及其用途
EP2325223B1 (en) 2002-10-30 2014-05-14 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
CA2541832C (en) 2003-10-10 2009-11-24 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
NZ547752A (en) * 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
NZ578297A (en) 2005-02-16 2010-11-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
KR101020024B1 (ko) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
WO2007065288A2 (en) 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
EP2124942B1 (en) 2007-03-23 2016-04-27 Basilea Pharmaceutica AG Combination medicaments for treating bacterial infections
ES2551916T3 (es) * 2007-07-23 2015-11-24 The Board Of Trustees Of The University Of Illinois Sistema para controlar la reactividad de los ácidos borónicos
KR20100059952A (ko) * 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110124634A1 (en) 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
WO2010104818A1 (en) * 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
KR101460095B1 (ko) 2009-06-08 2014-11-10 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
WO2011017125A1 (en) 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
CA2807546C (en) * 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (zh) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 一种6-氟水杨酸的制备方法
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
US20150018311A1 (en) 2012-01-09 2015-01-15 University of Tromsø Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2683329T3 (es) 2013-03-15 2018-09-26 Intrexon Corporation Diacilhidrazinas que contienen boro
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20170252351A1 (en) 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
US10624899B2 (en) 2016-07-14 2020-04-21 Achaogen, Inc. Combination products for the treatment of bacterial infections and methods of producing or dosing of same
CN106397455B (zh) 2016-08-30 2018-08-31 山东罗欣药业集团恒欣药业有限公司 一种抗感染药物头孢布烯晶体化合物及其组合物
CN106397454B (zh) 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
CN106432270A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106420760A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯组合物
CN106432272A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432271A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106420617A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯粉针剂
CN106397457A (zh) 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN109293678A (zh) 2018-11-20 2019-02-01 湖北凌晟药业有限公司 一种头孢布烯的制备方法
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas
EP3986419B1 (en) 2019-06-19 2025-05-14 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3152300C (en) 2019-08-29 2024-04-30 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
US20230151029A1 (en) 2020-03-18 2023-05-18 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
JP2024512793A (ja) 2021-04-05 2024-03-19 キューペックス バイオファーマ， インコーポレイテッド セフチブテン投与レジメン
EP4362950A4 (en) 2021-07-01 2025-08-13 Qpex Biopharma Inc CRYSTALLINE FORMS OF CEFTIBUTEN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) * 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anonymous, REGISTRY, (2005-02-15), Database accession no. 831209-98-4, URL: STN *
Anonymous, REGISTRY, (2005-02-15), Database accession no. 831210-03-8, URL: STN *

Also Published As

Publication number Publication date
IL263450B (en) 2022-01-01
ES2894251T3 (es) 2022-02-14
MX389349B (es) 2025-03-20
CA3026582A1 (en) 2018-01-04
KR20190025953A (ko) 2019-03-12
US10570159B2 (en) 2020-02-25
US11180512B2 (en) 2021-11-23
PH12018502747A1 (en) 2019-12-11
AU2017290060A1 (en) 2018-12-20
JP2019527196A (ja) 2019-09-26
US12509475B2 (en) 2025-12-30
CN109415386B (zh) 2022-04-19
ZA201808327B (en) 2022-04-28
CL2018003681A1 (es) 2019-04-26
US20180002351A1 (en) 2018-01-04
EP3478693B1 (en) 2021-07-21
BR112018077015B1 (pt) 2022-05-03
US20220056055A1 (en) 2022-02-24
US20250034175A1 (en) 2025-01-30
RU2018143900A3 (https=) 2020-09-29
MX2018015892A (es) 2019-06-20
CN109415386A (zh) 2019-03-01
IL263450A (en) 2019-01-31
DK3478693T3 (da) 2021-09-20
BR112018077015A2 (pt) 2019-04-02
KR102403296B1 (ko) 2022-05-27
US10294249B2 (en) 2019-05-21
JP7060245B2 (ja) 2022-04-26
EP3478693A4 (en) 2020-02-19
NZ749864A (en) 2025-06-27
US20190233443A1 (en) 2019-08-01
MY196909A (en) 2023-05-09
PL3478693T3 (pl) 2021-12-13
UA124464C2 (uk) 2021-09-22
RU2018143900A (ru) 2020-07-30
US20200181177A1 (en) 2020-06-11
US11999759B2 (en) 2024-06-04
WO2018005662A1 (en) 2018-01-04
PT3478693T (pt) 2021-10-25
SA518400742B1 (ar) 2023-02-28
EP3478693A1 (en) 2019-05-08
CO2018013978A2 (es) 2019-02-08
SG11201811549UA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
AU2017290060B2 (en) Boronic acid derivatives and therapeutic uses thereof
US10618918B2 (en) Substituted boronic acids as antimicrobials
AU2019256351B2 (en) Boronic acid derivatives and therapeutic uses thereof
AU2014204045A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP3145936A1 (en) Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
HK40000809B (en) Boronic acid derivatives and therapeutic uses thereof
RU2773346C2 (ru) Производные бороновой кислоты и их терапевтические применения
HK40045753B (en) Boronic acid derivatives and therapeutic uses thereof
HK40045753A (en) Boronic acid derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)